ArticleJournal of clinical medicine2022
Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Loneliness, Genetic Susceptibility, Brain Structure, and the Risk of Schizophrenia: A Large Prospective Study.Schizophrenia bulletin · 2026Article
- Early deviations from normative brain morphology and cortical microstructure in schizophrenia spectrum disorders.Translational psychiatry · 2026Article
- Cross-population validation of European GWAS loci for metabolic syndrome in Chinese schizophrenia.BMC psychiatry · 2026Article
- Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Clinical Evidence.Journal of clinical medicine · 2026Review
- Genetic Variants from Large Cohorts and Familial Studies Implicate Common Mechanisms in Schizophrenia.Biology · 2026Review
- Nutritional Management of Schizophrenia: Gut-Brain Axis Mechanisms and Dietary Interventions.Molecular neurobiology · 2026Review
- MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Diminished general and sexual hedonic capacity in schizophrenia - a clinical and neural characterization.Frontiers in psychiatry · 2026Article
- Machine learning algorithms and artificial neural networks for predicting schizophrenia using orbital parameters.Scientific reports · 2025Article
- DCM-ML: An Electroencephalography-based Classifier for Early Diagnosis of Schizophrenia Based on Dynamic Connectivity Matrices and Machine Learning Algorithms.Basic and clinical neuroscience · 2025Article
- A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Voice as a digital biomarker in schizophrenia: a scoping review protocol on the application of artificial intelligence.BMJ open · 2025Article
- Using blood methylomes to predict response to amisulpride in the first-episode psychosis in the OPTiMiSE cohort.Translational psychiatry · 2025Article
- Aberrant Expression of TH2LCRR and GATA3 in Peripheral Blood Mononuclear Cells of Patients with Acute-Phase Schizophrenia: Integrative Bioinformatics Analysis and Experimental Study.Molecular neurobiology · 2025Article
- The Left-Hand 2D:4D Ratio is Superior to the Right-Hand 2D:4D Ratio in Determining the Criminal Potential of Schizophrenia Patients.Alpha psychiatry · 2025Article
- Article
- Regulation ofInternational journal of molecular sciences · 2025Review
- Targeting GABAergic Hypofunction Associated with Schizophrenia: Identification of α1β2γ2GABA-A Receptor Ligands with Neuroprotective and Antipsychotic Properties.ACS chemical neuroscience · 2025Article
- Impact of Psychiatric Nurse-Led Programs on Self-Care Practices, Medication Adherence, and Psychological Health in Schizophrenia Patients: A Mixed-Methods Investigation of Caregiver Experiences.Journal of pharmacy & bioallied sciences · 2025Article
- Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).Molecular medicine reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although schizophrenia is currently conceptualized as being characterized as a syndrome that includes a collection of signs and symptoms, there is strong evidence of heterogeneous and complex underpinned etiological, etiopathogenetic, and psychopathological mechanisms, which are still under investigation. Therefore, the present viewpoint review is aimed at providing some insights into the recently investigated schizophrenia research fields in order to discuss the potential future research directions in schizophrenia research. The traditional schizophrenia construct and diagnosis were progressively revised and revisited, based on the recently emerging neurobiological, genetic, and epidemiological research. Moreover, innovative diagnostic and therapeutic approaches are pointed to build a new construct, allowing the development of better clinical and treatment outcomes and characterization for schizophrenic individuals, considering a more patient-centered, personalized, and tailored-based dimensional approach. Further translational studies are needed in order to integrate neurobiological, genetic, and environmental studies into clinical practice and to help clinicians and researchers to understand how to redesign a new schizophrenia construct.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.